Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1,490 | $1,114 | $1,020 | $966 |
| Short-Term Investments | $1,234 | $1,744 | $1,613 | $1,728 |
| Receivables | $965 | $567 | $418 | $405 |
| Inventory | $75 | $72 | $66 | $79 |
| Other Curr. Assets | $188 | $147 | $152 | $117 |
| Total Curr. Assets | $3,953 | $3,644 | $3,268 | $3,295 |
| Property Plant & Equip (Net) | $693 | $692 | $696 | $694 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $54 | $0 | $0 | $0 |
| Tax Assets | $99 | $104 | $107 | $117 |
| Other NC Assets | $53 | $126 | $142 | $134 |
| Total NC Assets | $899 | $922 | $946 | $945 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $4,852 | $4,566 | $4,214 | $4,240 |
| Liabilities | – | – | – | – |
| Payables | $118 | $102 | $97 | $88 |
| Short-Term Debt | $160 | $98 | $82 | $113 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $3 | $15 | $28 | $55 |
| Other Curr. Liab. | $1,275 | $121 | $118 | $214 |
| Total Curr. Liab. | $1,555 | $1,301 | $1,076 | $1,186 |
| LT Debt | $2,389 | $2,372 | $2,364 | $2,359 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $449 | $418 | $428 | $398 |
| Total NC Liab. | $3,062 | $3,015 | $3,023 | $2,987 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $268 | $271 | $276 | $271 |
| Total Liabilities | $4,618 | $4,315 | $4,098 | $4,173 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1 | $1 | $1 | $1 |
| Retained Earnings | -$7,160 | -$7,412 | -$7,345 | -$7,288 |
| AOCI | -$22 | -$30 | -$38 | -$35 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $234 | $251 | $115 | $67 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $4,852 | $4,566 | $4,214 | $4,240 |
| Net Debt | $1,060 | $1,356 | $1,427 | $1,506 |